ARS Pharmaceuticals (SPRY) EBIT Growth (1y) (2021 - 2026)
ARS Pharmaceuticals (SPRY) EBIT Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 2,150.96% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -61.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.78% |
| Dec 31, 2025 | -187.86% |
| Sep 30, 2025 | -144.58% |
| Jun 30, 2025 | -210.39% |
| Mar 31, 2025 | -181.81% |
| Dec 31, 2024 | 561.54% |
| Sep 30, 2024 | -20.97% |
| Jun 30, 2024 | 25.54% |
| Mar 31, 2024 | 29.50% |
| Dec 31, 2023 | 33.78% |
| Sep 30, 2023 | -171.16% |
| Jun 30, 2023 | -224.76% |
| Mar 31, 2023 | -163.60% |
| Dec 31, 2022 | -133.12% |
| Sep 30, 2022 | 70.77% |
| Jun 30, 2022 | 74.12% |
| Mar 31, 2022 | 62.41% |
| Dec 31, 2021 | 455.87% |
| Sep 30, 2021 | -179.60% |
| Jun 30, 2021 | -279.25% |